8/23 Late treatment study
et al., Nutrients, doi:10.3390/nu13082898 (Peer Reviewed)
Oxygen Sparing Effect of Bacteriotherapy in COVID-19
Oxygen Sparing Effect of Bacteriotherapy in COVID-19
Prospective analysis of 69 severe COVID-19 patients requiring non-invasive oxygen therapy, 40 treated with probiotic formulation SLAB51, showing lower oxygen requirements and higher blood levels of pO2, O2Hb and SaO2 with treatment. Authors suggest that enzymes in SLAB51 could reduce oxygen requirements in intestinal cells, resulting in more oxygen available for other organs.
Ceccarelli et al., 8/23/2021, prospective, Italy, Europe, peer-reviewed, 10 authors.
risk of death, 70.4% lower, RR 0.30, p = 0.42, treatment 0 of 40 (0.0%), control 1 of 29 (3.4%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 81.9% lower, RR 0.18, p = 0.15, treatment 1 of 40 (2.5%), control 4 of 29 (13.8%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.